Identification of population at risk for future Clostridium difficile infection following hospital discharge to be targeted for vaccine trials

Vaccine

Volumn 33, Issue 46, 2015, Pages 6241-6249

  Baggs, James ^a   Yousey Hindes, Kimberly ^b   Ashley, Elizabeth Dodds ^c   Meek, James ^b   Dumyati, Ghinwa ^c   Cohen, Jessica ^a,d   Wise, Matthew E ^a   McDonald, L Clifford ^a   Lessa, Fernanda C ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b YALE UNIVERSITY   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d ATLANTA RESEARCH AND EDUCATION FOUNDATION   (United States)

Author keywords

Administrative data; Anti bacterial agents; Clostridium difficile infection; Health care associated infections; Vaccines

Indexed keywords

CEPHALOSPORIN; CLINDAMYCIN; QUINOLONE DERIVATIVE; BACTERIAL VACCINE;

ADULT; AGE; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; FEMALE; HIGH RISK POPULATION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ADOLESCENT; AGED; CLINICAL TRIAL (TOPIC); CLOSTRIDIUM INFECTIONS; CONNECTICUT; DECISION SUPPORT SYSTEM; HOSPITAL; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; NEW YORK; PEPTOCLOSTRIDIUM DIFFICILE; RISK ASSESSMENT; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTERIAL VACCINES; CLINICAL TRIALS AS TOPIC; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CONNECTICUT; DECISION SUPPORT TECHNIQUES; FEMALE; HOSPITALS; HUMANS; MALE; MIDDLE AGED; NEW YORK; PATIENT DISCHARGE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; YOUNG ADULT;

EID: 84946600120     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.09.078     Document Type: Article

References (19)

1. Magill S.S., Edwards J.R., Bamberg W., Beldavs Z.G., Dumyati G., Kainer M.A., et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014, 370:1198-1208.
2. Lessa F.C., Mu Y., Bamberg W.M., Beldavs Z.G., Dumyati G.K., Dunn J.R., et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015, 372:825-834.
3. Steiner C., Barrett M., Terrel L. HCUP Projections: Clostridium difficile hospitalizations 2011 to 2012. HCUP Projections Report 2012, U.S. Agency for Healthcare Research and Quality.
4. Hall A.J., Curns A.T., McDonald L.C., Parashar U.D., Lopman B.A. The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999-2007. Clin Infect Dis: Off Publ Infect Dis Soc Am 2012, 55:216-223.
5. McDonald L.C., Lessa F., Sievert D., Wise M., Herrera R., Gould C., et al. Vital signs: preventing Clostridium difficile infections. MMWR Morbid Mortal Weekly Rep 2012, 61:157-162.
6. Miller B.A., Chen L.F., Sexton D.J., Anderson D.J. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol: Off J Soc Hosp Epidemiol Am 2011, 32:387-390.
7. Measuring the scope of Clostridium difficile Infection in the United States. Centers for Disease Control and Prevention; 2012.
8. Elixhauser A., Steiner C., Palmer L. Clinical classifications software (CCS) 2011, U.S. Agency for Healthcare Research and Quality.
9. Leuzzi R., Adamo R., Scarselli M. Vaccines against Clostridium difficile. Hum Vaccine Immunother 2014, 10:1466-1477.
10. Foglia G., Shah S., Luxemburger C., Pietrobon P.J. Clostridium difficile: development of a novel candidate vaccine. Vaccine 2012, 30:4307-4309.
11. Gagne J.J., Glynn R.J., Avorn J., Levin R., Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol 2011, 64:749-759.
12. Zilberberg M.D., Reske K., Olsen M., Yan Y., Dubberke E.R. Development and validation of a recurrent Clostridium difficile risk-prediction model. J Hosp Med: Off Publ Soc Hosp Med 2014, 9:418-423.
13. Dubberke E.R., Yan Y., Reske K.A., Butler A.M., Doherty J., Pham V., et al. Development and validation of a Clostridium difficile infection risk prediction model. Infect Control Hosp Epidemiol: Off J Soc Hosp Epidemiol Am 2011, 32:360-366.
14. Chandra S., Thapa R., Marur S., Jani N. Validation of a clinical prediction scale for hospital-onset Clostridium difficile infection. J Clin Gastroenterol 2014, 48:419-422.
15. Strom B.L., Carson J.L. Use of automated databases for pharmacoepidemiology research. Epidemiol Rev 1990, 12:87-107.
16. Verstraeten T., DeStefano F., Chen R.T., Miller E. Vaccine safety surveillance using large linked databases: opportunities, hazards and proposed guidelines. Expert Rev Vaccines 2003, 2:21-29.
17. Mullooly J.P., Donahue J.G., DeStefano F., Baggs J., Eriksen E., for the VSD Data Quality Working Group Predictive value of ICD-9-CM codes used in vaccine safety research. Methods Inform Med 2008, 47:328-335.
18. Baggs J., Lessa F.C. Validation of risk score to identify future Clostridium difficile Infection following hospital discharge in a cohort of hospitals submitting data to a hospital drug database. International conference on emerging infectious diseases 2015.
19. Fridkin S., Baggs J., Fagan R., Magill S., Pollack L.A., Malpiedi P., et al. Vital signs: improving antibiotic use among hospitalized patients. MMWR Morbid Mortal Weekly Rep 2014, 63:194-200.